LB Pharmaceuticals Inc Common Stock

LBRXNASDAQ • USD
43.22 USD
↗ 0.21 (0.48%)🟢LIVE (AS OF 09:35 AM EST)
🟢Market: OPEN

LB Pharmaceuticals Inc Common Stock (LBRX) is currently trading at $43.22. LBRX shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, LBRX trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 13, 2026.

Open?$43.60
High?$44.00
Low?$42.86
Prev. Close?$43.01
Volume?5.1K
Avg. Volume?410.3K
VWAP?$43.17
Rel. Volume?0.01x
Bid / Ask
Bid?$27.61 × 100
Ask?$57.00 × 100
Spread?$29.39
Midpoint?$42.31
Valuation & Ratios
Market Cap?1.4B
Shares Out?N/A
Float?24.2M
Float %?84.5%
P/E Ratio?N/A
P/B Ratio?3.33
EPS?-$4.36
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Employees
27
Market Cap
1.4B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2025-09-11
Address
575 MADISON AVENUE
NEW YORK, NY 10022
Phone: 917-450-6581
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
25
Piotroski F-Score?0/9Weak
Altman Z-Score?22.57Safe
Confidence?41%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?25.60%Squeeze Risk
Short Interest?6.2M
Days to Cover?18.0
Free Float24.2M
Avg Daily Volume344.7K
Settlement Date2026-10-30
Financial Health
Current Ratio?14.78Strong
Quick Ratio?14.78Strong
Cash Ratio?7.11Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
51
3.33FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-7.7CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
5
-33.8%WEAK▾
ROA?
S&P
3
-31.1%WEAK▾
Cash Flow & Enterprise
FCF?$-143819000
Enterprise Value?$1.2B
Fundamentals ratios updated end of day